Reviewing CytoDyn (OTCMKTS:CYDY) and Enliven Therapeutics (NASDAQ:ELVN)

Enliven Therapeutics (NASDAQ:ELVN) and CytoDyn (OTCMKTS:CYDY) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Volatility & Risk

Enliven Therapeutics has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, CytoDyn has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.

Valuation and Earnings

This table compares Enliven Therapeutics and CytoDyn”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$89.02 million	($1.84)	-14.69
CytoDyn	N/A	N/A	$3.74 million	($0.03)	-8.62

Enliven Therapeutics is trading at a lower price-to-earnings ratio than CytoDyn, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Enliven Therapeutics and CytoDyn, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1	0	4	0	2.60
CytoDyn	0	0	0	0	0.00

Enliven Therapeutics presently has a consensus target price of $41.00, suggesting a potential upside of 51.68%. Given Enliven Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Enliven Therapeutics is more favorable than CytoDyn.

Profitability

This table compares Enliven Therapeutics and CytoDyn’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-24.88%	-23.96%
CytoDyn	N/A	N/A	-175.37%

Insider and Institutional Ownership

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 5.1% of CytoDyn shares are held by institutional investors. 25.9% of Enliven Therapeutics shares are held by insiders. Comparatively, 1.0% of CytoDyn shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Enliven Therapeutics beats CytoDyn on 6 of the 11 factors compared between the two stocks.

About Enliven Therapeutics

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

About CytoDyn

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.